<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35596795</PMID><DateCompleted><Year>2022</Year><Month>09</Month><Day>14</Day></DateCompleted><DateRevised><Year>2022</Year><Month>09</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-1459</ISSN><JournalIssue CitedMedium="Internet"><Volume>269</Volume><Issue>10</Issue><PubDate><Year>2022</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Journal of neurology</Title><ISOAbbreviation>J Neurol</ISOAbbreviation></Journal><ArticleTitle>A phase I/IIa clinical trial of autologous hematopoietic stem cell transplantation in amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>5337</StartPage><EndPage>5346</EndPage><MedlinePgn>5337-5346</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00415-022-11185-w</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To verify the safety and potential effect on ALS progression of a low-intensity immunosuppressive regimen followed by autologous hematopoietic stem cell transplantation (aHSCT) in amyotrophic lateral sclerosis (ALS) patients.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">ALS eligible patients underwent a set of clinical and laboratory evaluations at T-4 (screening), T-1 (pre-treatment visit), and for the 12 consecutive months after treatment (T3, T6, T9, T12). We evaluated the tolerability of the procedure, its efficacy on clinical course and quality of life (QoL).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Eight of the 11 ALS patients enrolled received the established immunoablative protocol. The procedure was well tolerated and side effects were those expected. One patient died 4&#xa0;months after the conditioning regimen and another patient underwent tracheotomy just before T3 for a sudden respiratory failure, but he is still alive 4&#xa0;years after the procedure without being ventilated any more. A third patient died 10&#xa0;months after conditioning. In the other cases, there was no statistical difference in all functional measures and QoL pre- and post-treatment; however, a transitory slopes' reduction of ALSFRS-R and seated SVC% after the conditioning procedures was reported. Moreover, although not statistically significant, trends of reduction of CD4&#x2009;+&#x2009;and increment of CD8&#x2009;+&#x2009;were found.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">aHSCT was overall well tolerated, but it was not followed by any significant modification in disease progression. Considering the negative results of this small trial, further studies aimed to evaluate the possible efficacy of the aHSCT using a higher-intensity regimen should be carefully and with caution evaluated.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lunetta</LastName><ForeName>Christian</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-4788-1875</Identifier><AffiliationInfo><Affiliation>NEMO Clinical Center Milano, Fondazione Serena Onlus, Piazza Ospedale Maggiore 3, 20162, Milan, Italy. christian.lunetta@centrocliniconemo.it.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurorehabilitation Department of Milano Institute, Istituti Clinici Scientifici Maugeri IRCCS, Milan, Italy. christian.lunetta@centrocliniconemo.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lizio</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>NEMO Clinical Center Milano, Fondazione Serena Onlus, Piazza Ospedale Maggiore 3, 20162, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cabona</LastName><ForeName>Corrado</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, IRCCS Ospedale Policlinico San Martino, Genova, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gerardi</LastName><ForeName>Francesca</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>NEMO Clinical Center Milano, Fondazione Serena Onlus, Piazza Ospedale Maggiore 3, 20162, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sansone</LastName><ForeName>Valeria Ada</ForeName><Initials>VA</Initials><AffiliationInfo><Affiliation>NEMO Clinical Center Milano, Fondazione Serena Onlus, Piazza Ospedale Maggiore 3, 20162, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurorehabilitation Unit, University of Milan, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Corbo</LastName><ForeName>Massimo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurorehabilitation Sciences, Casa Cura Policlinico (CCP), Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scial&#xf2;</LastName><ForeName>Carlo</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Quantitative Biomedicine, University of Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Angelucci</LastName><ForeName>Emanuele</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Hematology and Cell Therapy, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gualandi</LastName><ForeName>Francesca</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Hematology and Cell Therapy, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marenco</LastName><ForeName>Paola</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Division of Haematology, ASST GOM Niguarda, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grillo</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Division of Haematology, ASST GOM Niguarda, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cairoli</LastName><ForeName>Roberto</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Division of Haematology, ASST GOM Niguarda, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cesana</LastName><ForeName>Clara</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, ASST GOM Niguarda, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saccardi</LastName><ForeName>Riccardo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Cell Therapy and Transfusion Medicine Unit, Careggi University Hospital, Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Melazzini</LastName><ForeName>Mario Giovanni</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>Istituti Clinici Scientifici Maugeri, Pavia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mancardi</LastName><ForeName>Gianluigi</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Istituti Clinici Scientifici Maugeri, Pavia, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosciences, Rehabilitation, Ophtalmology, Genetics, Maternal and Child Health, University of Genoa, Genoa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caponnetto</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Rehabilitation, Ophtalmology, Genetics, Maternal and Child Health, University of Genoa, Genoa, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>05</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>J Neurol</MedlineTA><NlmUniqueID>0423161</NlmUniqueID><ISSNLinking>0340-5354</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018380" MajorTopicYN="Y">Hematopoietic Stem Cell Transplantation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019172" MajorTopicYN="N">Transplantation Conditioning</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014182" MajorTopicYN="N">Transplantation, Autologous</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Cyclophosphamide</Keyword><Keyword MajorTopicYN="N">Disease progression</Keyword><Keyword MajorTopicYN="N">Hematopoietic stem cell transplantation</Keyword><Keyword MajorTopicYN="N">T-reg</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>2</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>5</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>5</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>5</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>5</Month><Day>21</Day><Hour>11</Hour><Minute>14</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35596795</ArticleId><ArticleId IdType="doi">10.1007/s00415-022-11185-w</ArticleId><ArticleId IdType="pii">10.1007/s00415-022-11185-w</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Thonhoff JR, Simpson EP, Appel SH (2018) Neuroinflammatory mechanisms in amyotrophic lateral sclerosis pathogenesis. Curr Opin Neurol 31(5):635&#x2013;639</Citation><ArticleIdList><ArticleId IdType="pubmed">30048339</ArticleId><ArticleId IdType="doi">10.1097/WCO.0000000000000599</ArticleId></ArticleIdList></Reference><Reference><Citation>Graves MC, Fiala M, Dinglasan LA, Liu NQ, Sayre J, Chiappelli F, van Kooten C, Vinters HV (2004) Inflammation in amyotrophic lateral sclerosis spinal cord and brain is mediated by activated macrophages, mast cells and T cells. Amyotroph Lateral Scler Other Motor Neuron Disord 5(4):213&#x2013;219</Citation><ArticleIdList><ArticleId IdType="pubmed">15799549</ArticleId><ArticleId IdType="doi">10.1080/14660820410020286</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawamata T, Akiyama H, Yamada T, McGeer PL (1992) Immunologic reactions in amyotrophic lateral sclerosis brain and spinal cord tissue. Am J Pathol 140(3):691&#x2013;707</Citation><ArticleIdList><ArticleId IdType="pubmed">1347673</ArticleId><ArticleId IdType="pmc">1886170</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall ED, Oostveen JA, Gurney ME (1998) Relationship of microglial and astrocytic activation to disease onset and progression in a transgenic model of familial ALS. Glia 23(3):249&#x2013;256</Citation><ArticleIdList><ArticleId IdType="pubmed">9633809</ArticleId><ArticleId IdType="doi">10.1002/(SICI)1098-1136(199807)23:3&lt;249::AID-GLIA7&gt;3.0.CO;2-#</ArticleId></ArticleIdList></Reference><Reference><Citation>Hooten KG, Beers DR, Zhao W, Appel SH (2015) Protective and toxic neuroinflammation in amyotrophic lateral sclerosis. Neurotherapeutics 12(2):364&#x2013;375</Citation><ArticleIdList><ArticleId IdType="pubmed">25567201</ArticleId><ArticleId IdType="pmc">4404435</ArticleId><ArticleId IdType="doi">10.1007/s13311-014-0329-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheean RK, McKay FC, Cretney E, Bye CR, Perera ND, Tomas D, Weston RA, Scheller KJ, Djouma E, Menon P et al (2018) Association of regulatory T-cell expansion with progression of amyotrophic lateral sclerosis: a study of humans and a transgenic mouse model. JAMA Neurol 75(6):681&#x2013;689</Citation><ArticleIdList><ArticleId IdType="pubmed">29507931</ArticleId><ArticleId IdType="pmc">5885208</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2018.0035</ArticleId></ArticleIdList></Reference><Reference><Citation>Rashid Chehreh Bargh S, Tafakhori A, Masoumi F, Rahmani F, Ahmadi M, Namdar A, Azimi M, Tavasolian P, Habibi S, Zamani B et al (2018) Evaluation of regulatory T lymphocytes and IL2Ra and FOXP3 gene expression in peripheral mononuclear cells from patients with amyotrophic lateral sclerosis. Ir J Med Sci 187(4):1065&#x2013;1071</Citation><ArticleIdList><ArticleId IdType="pubmed">29574662</ArticleId><ArticleId IdType="doi">10.1007/s11845-018-1793-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao W, Beers DR, Liao B, Henkel JS, Appel SH (2012) Regulatory T lymphocytes from ALS mice suppress microglia and effector T lymphocytes through different cytokine-mediated mechanisms. Neurobiol Dis 48(3):418&#x2013;428</Citation><ArticleIdList><ArticleId IdType="pubmed">22820142</ArticleId><ArticleId IdType="pmc">3897268</ArticleId><ArticleId IdType="doi">10.1016/j.nbd.2012.07.008</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao W, Beers DR, Appel SH (2013) Immune-mediated mechanisms in the pathoprogression of amyotrophic lateral sclerosis. J Neuroimmune Pharmacol 8(4):888&#x2013;899</Citation><ArticleIdList><ArticleId IdType="pubmed">23881705</ArticleId><ArticleId IdType="pmc">4126425</ArticleId><ArticleId IdType="doi">10.1007/s11481-013-9489-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Wosiski-Kuhn M, Lyon MS, Caress J, Milligan C (2019) Inflammation, immunity, and amyotrophic lateral sclerosis: II. immune-modulating therapies. Muscle Nerve 59(1):23&#x2013;33</Citation><ArticleIdList><ArticleId IdType="pubmed">29979478</ArticleId><ArticleId IdType="doi">10.1002/mus.26288</ArticleId></ArticleIdList></Reference><Reference><Citation>Gourie-Devi M, Nalini A, Subbakrishna DK (1997) Temporary amelioration of symptoms with intravenous cyclophosphamide in amyotrophic lateral sclerosis. J Neurol Sci 150(2):167&#x2013;172</Citation><ArticleIdList><ArticleId IdType="pubmed">9268246</ArticleId><ArticleId IdType="doi">10.1016/S0022-510X(97)00083-X</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith SA, Miller RG, Murphy JR, Ringel SP (1994) Treatment of ALS with high dose pulse cyclophosphamide. J Neurol Sci 124(Suppl):84&#x2013;87</Citation><ArticleIdList><ArticleId IdType="pubmed">7807153</ArticleId><ArticleId IdType="doi">10.1016/0022-510X(94)90188-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Eglitis MA, Mezey E (1997) Hematopoietic cells differentiate into both microglia and macroglia in the brains of adult mice. Proc Natl Acad Sci USA 94(8):4080&#x2013;4085</Citation><ArticleIdList><ArticleId IdType="pubmed">9108108</ArticleId><ArticleId IdType="pmc">20571</ArticleId><ArticleId IdType="doi">10.1073/pnas.94.8.4080</ArticleId></ArticleIdList></Reference><Reference><Citation>Priller J, Fl&#xfc;gel A, Wehner T, Boentert M, Haas CA, Prinz M, Fern&#xe1;ndez-Klett F, Prass K, Bechmann I, de Boer BA et al (2001) Targeting gene-modified hematopoietic cells to the central nervous system: use of green fluorescent protein uncovers microglial engraftment. Nat Med 7(12):1356&#x2013;1361</Citation><ArticleIdList><ArticleId IdType="pubmed">11726978</ArticleId><ArticleId IdType="doi">10.1038/nm1201-1356</ArticleId></ArticleIdList></Reference><Reference><Citation>Lampron A, Pimentel-Coelho PM, Rivest S (2013) Migration of bone marrow-derived cells into the central nervous system in models of neurodegeneration. J Comp Neurol 521(17):3863&#x2013;3876</Citation><ArticleIdList><ArticleId IdType="pubmed">23682015</ArticleId><ArticleId IdType="doi">10.1002/cne.23463</ArticleId></ArticleIdList></Reference><Reference><Citation>Terashima T, Kojima H, Urabe H, Yamakawa I, Ogawa N, Kawai H, Chan L, Maegawa H (2014) Stem cell factor-activated bone marrow ameliorates amyotrophic lateral sclerosis by promoting protective microglial migration. J Neurosci Res 92(7):856&#x2013;869</Citation><ArticleIdList><ArticleId IdType="pubmed">24936617</ArticleId><ArticleId IdType="pmc">4061499</ArticleId><ArticleId IdType="doi">10.1002/jnr.23368</ArticleId></ArticleIdList></Reference><Reference><Citation>Garbuzova-Davis S, Haller E, Navarro S, Besong TE, Boccio KJ, Hailu S, Khatib M, Sanberg PR, Appel SH, Borlongan CV (2018) Transplantation of human bone marrow stem cells into symptomatic ALS mice enhances structural and functional blood-spinal cord barrier repair. Exp Neurol 310:33&#x2013;47</Citation><ArticleIdList><ArticleId IdType="pubmed">30172620</ArticleId><ArticleId IdType="pmc">6203661</ArticleId><ArticleId IdType="doi">10.1016/j.expneurol.2018.08.012</ArticleId></ArticleIdList></Reference><Reference><Citation>Garbuzova-Davis S, Kurien C, Haller E, Eve DJ, Navarro S, Steiner G, Mahendrasah A, Hailu S, Khatib M, Boccio KJ et al (2015) Human bone marrow endothelial progenitor cell transplantation into symptomatic ALS mice delays disease progression and increases motor neuron survival by repairing blood-spinal cord barrier. Sci Rep 2019 9(1):5280</Citation></Reference><Reference><Citation>Sharrack B, Saccardi R, Alexander T, Badoglio M, Burman J, Farge D, Greco R, Jessop H, Kazmi M, Kirgizov K et al (2020) Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: updated guidelines and recommendations from the EBMT Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of EBMT and ISCT (JACIE). Bone Marrow Transplant 55(2):283&#x2013;306</Citation><ArticleIdList><ArticleId IdType="pubmed">31558790</ArticleId><ArticleId IdType="doi">10.1038/s41409-019-0684-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Muraro PA, Martin R, Mancardi GL, Nicholas R, Sormani MP, Saccardi R (2017) Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis. Nat Rev Neurol 13(7):391&#x2013;405</Citation><ArticleIdList><ArticleId IdType="pubmed">28621766</ArticleId><ArticleId IdType="doi">10.1038/nrneurol.2017.81</ArticleId></ArticleIdList></Reference><Reference><Citation>Muraro PA, Abrahamsson SV (2010) Resetting autoimmunity in the nervous system: the role of hematopoietic stem cell transplantation. Curr Op Investig Drugs 11:1265&#x2013;1275</Citation></Reference><Reference><Citation>Mancardi G, Saccardi R (2008) Autologous haematopoietic stem-cell transplantation in multiple sclerosis. Lancet Neurol 7(7):626&#x2013;636</Citation><ArticleIdList><ArticleId IdType="pubmed">18565456</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(08)70138-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Sormani MP, Muraro PA, Schiavetti I, Signori A, Laroni A, Saccardi R, Mancardi GL (2017) Autologous hematopoietic stem cell transplantation in multiple sclerosis: a meta-analysis [published correction appears in Neurology 2017:11;89(2):215]. Neurology 88(22):2115&#x2013;2122</Citation><ArticleIdList><ArticleId IdType="pubmed">28455383</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000003987</ArticleId></ArticleIdList></Reference><Reference><Citation>Nash RA, Hutton GJ, Racke MK, Popat U, Devine SM, Steinmiller KC, Griffith LM, Muraro PA, Openshaw H, Sayre PH et al (2017) High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS. Neurology 88(9):842&#x2013;852</Citation><ArticleIdList><ArticleId IdType="pubmed">28148635</ArticleId><ArticleId IdType="pmc">5331868</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000003660</ArticleId></ArticleIdList></Reference><Reference><Citation>Atkins HL, Bowman M, Allan D, Anstee G, Arnold DL, Bar-Or A, Bence-Bruckler I, Birch P, Bredeson C, Chen J et al (2016) Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial. Lancet 388(10044):576&#x2013;585</Citation><ArticleIdList><ArticleId IdType="pubmed">27291994</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(16)30169-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Curro D, Vuolo L, Gualandi F, Bacigalupo A, Roccatagliata L, Capello E, Uccelli A, Saccardi R, Sormani MP, Mancardi G (2015) Low intensity lympho-ablative regimen followed by autologous hematopoietic stem cell transplantation in severe forms of multiple sclerosis: a MRI-based clinical study. Mult Scler 21(11):1423&#x2013;1430</Citation><ArticleIdList><ArticleId IdType="pubmed">25583838</ArticleId><ArticleId IdType="doi">10.1177/1352458514564484</ArticleId></ArticleIdList></Reference><Reference><Citation>Leis AA, Ross MA, Verheijde JL, Leis JF (2016) Immunoablation and stem cell transplantation in amyotrophic lateral sclerosis: the ultimate test for the autoimmune pathogenesis hypothesis. Front Neurol 7:12</Citation><ArticleIdList><ArticleId IdType="pubmed">26903945</ArticleId><ArticleId IdType="pmc">4749695</ArticleId></ArticleIdList></Reference><Reference><Citation>Appel SH, Engelhardt JI, Henkel JS, Siklos L, Beers DR, Yen AA, Simpson EP, Luo Y, Carrum G, Heslop HE et al (2008) Hematopoietic stem cell transplantation in patients with sporadic amyotrophic lateral sclerosis. Neurology 71(17):1326&#x2013;1334</Citation><ArticleIdList><ArticleId IdType="pubmed">18936424</ArticleId><ArticleId IdType="doi">10.1212/01.wnl.0000327668.43541.22</ArticleId></ArticleIdList></Reference><Reference><Citation>Fournier CN, Schoenfeld D, Berry JD, Cudkowicz ME, Chan J, Quinn C, Brown RH, Salameh JS, Tansey MG, Beers DR et al (2018) An open label study of a novel immunosuppression intervention for the treatment of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener 19(3&#x2013;4):242&#x2013;249</Citation><ArticleIdList><ArticleId IdType="pubmed">29308669</ArticleId><ArticleId IdType="doi">10.1080/21678421.2017.1421666</ArticleId></ArticleIdList></Reference><Reference><Citation>Khalid SI, Ampie L, Kelly R, Ladha SS, Dardis C (2017) Immune modulation in the treatment of amyotrophic lateral sclerosis: a review of clinical trials. Front Neurol 8:486</Citation><ArticleIdList><ArticleId IdType="pubmed">28993751</ArticleId><ArticleId IdType="pmc">5622209</ArticleId><ArticleId IdType="doi">10.3389/fneur.2017.00486</ArticleId></ArticleIdList></Reference><Reference><Citation>Longinetti E, Fang F (2019) Epidemiology of amyotrophic lateral sclerosis: an update of recent literature. Curr Opin Neurol 32(5):771&#x2013;776</Citation><ArticleIdList><ArticleId IdType="pubmed">31361627</ArticleId><ArticleId IdType="pmc">6735526</ArticleId><ArticleId IdType="doi">10.1097/WCO.0000000000000730</ArticleId></ArticleIdList></Reference><Reference><Citation>Lunetta C, Lizio A, Maestri E, Sansone VA, Mora G, Miller RG, Appel SH, Chi&#xf2; A (2017) Serum C-reactive protein as a prognostic biomarker in amyotrophic lateral sclerosis. JAMA Neurol 74(6):660&#x2013;667</Citation><ArticleIdList><ArticleId IdType="pubmed">28384752</ArticleId><ArticleId IdType="pmc">5822215</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2016.6179</ArticleId></ArticleIdList></Reference><Reference><Citation>Burt RK, Balabanov R, Burman J, Sharrack B, Snowden JA, Oliveira MC, Fagius J, Rose J, Nelson F, Barreira AA et al (2019) Effect of nonmyeloablative hematopoietic stem cell transplantation vs continued disease-modifying therapy on disease progression in patients with relapsing-remitting multiple sclerosis: a randomized clinical trial. JAMA 321(2):165&#x2013;174</Citation><ArticleIdList><ArticleId IdType="pubmed">30644983</ArticleId><ArticleId IdType="pmc">6439765</ArticleId><ArticleId IdType="doi">10.1001/jama.2018.18743</ArticleId></ArticleIdList></Reference><Reference><Citation>Capotondo A, Milazzo R, Politi LS, Quattrini A, Palini A, Plati T, Merella S, Nonis A, di Serio C, Montini E et al (2012) Brain conditioning is instrumental for successful microglia reconstitution following hematopoietic stem cell transplantation. Proc Natl Acad Sci USA 109(37):15018&#x2013;15023</Citation><ArticleIdList><ArticleId IdType="pubmed">22923692</ArticleId><ArticleId IdType="pmc">3443128</ArticleId><ArticleId IdType="doi">10.1073/pnas.1205858109</ArticleId></ArticleIdList></Reference><Reference><Citation>Motataianu A, Barcutean L, Balasa R (2020) Neuroimmunity in amyotrophic lateral sclerosis: focus on microglia. Amyotroph Lateral Scler Frontotemporal Degener 21(3&#x2013;4):159&#x2013;166</Citation><ArticleIdList><ArticleId IdType="pubmed">31903792</ArticleId><ArticleId IdType="doi">10.1080/21678421.2019.1708949</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>